Premium
Somatostatin and neuropeptide Y immunoreactivity in parkinson's disease dementia with alzheimer's changes
Author(s) -
Flint Beal M.,
Clevens Ross A.,
Mazurek Michael F.
Publication year - 1988
Publication title -
synapse
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.809
H-Index - 106
eISSN - 1098-2396
pISSN - 0887-4476
DOI - 10.1002/syn.890020415
Subject(s) - somatostatin , dementia , parkinson's disease , alzheimer's disease , degenerative disease , neuropeptide y receptor , medicine , pathology , neuropeptide , neuroscience , disease , psychology , endocrinology , receptor
Somatostatin‐like immunoreactivity (SLI) and neuropeptide Y‐like immunoreactivity (NPYLI) were measured in postmortem brain tissue from 12 control patients and 13 demented Parkinsonian patients who had Alzheimer‐type cortical pathology. Twenty‐two cortical regions were examined. Significant reductions in cortical SLI were found in 17 regions, while significant reductions in cortical NPYLI were found in nine regions. The reductions in SLI were typically 50–60%, while NPYLI reductions were 20–30%. These findings are similar to those in Alzheimer's disease (AD) and are consistent with a previous report of a dissociation between reductions in SLI and NPYLI in Parkinson's disease (PD) with dementia.